Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 27015562
Booth L, et al. (2016) [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget 7, 23608-32 27015562
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed decrease

S355-p - ATG13 (human)
Modsite: DTETVSNssEGRAsP SwissProt Entrez-Gene
Orthologous residues
ATG13 (human): S355‑p, ATG13 iso5 (human): S388‑p, ATG13 (mouse): S354‑p, ATG13 (rat): S317‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed increase
sorafenib, pemetrexed decrease

T300-p - ATG16L1 (human)
Modsite: VPQDNVDtHPGsGKE SwissProt Entrez-Gene
Orthologous residues
ATG16L1 (human): T300‑p, ATG16L1 iso2 (human): T281‑p, ATG16L1 iso3 (human): T300‑p, ATG16L1 (mouse): T300‑p, ATG16L1 iso3 (mouse): T316‑p, ATG16L1 (rat): T300‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies

S13-p - CDC37 (human)
Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene
Orthologous residues
CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed decrease

S536-p - NFkB-p65 (human)
Modsite: sGDEDFSsIADMDFS SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed increase

T802-p - PERK (human)
Modsite: YVRSRERtssSIVFE SwissProt Entrez-Gene
Orthologous residues
PERK (human): T802‑p, PERK (mouse): T799‑p, PERK (rat): T794‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed decrease

T982-p - PERK (human)
Modsite: MPAYARHtGQVGTKL SwissProt Entrez-Gene
Orthologous residues
PERK (human): T982‑p, PERK (mouse): T980‑p, PERK (rat): T974‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed increase

S317-p - ULK1 (human)
Modsite: SHLASPPsLGEMQQL SwissProt Entrez-Gene
Orthologous residues
ULK1 (human): S317‑p, ULK1 (mouse): S317‑p, ULK1 (rat): S317‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed increase

S758-p - ULK1 (human)
Modsite: PVVFtVGsPPsGStP SwissProt Entrez-Gene
Orthologous residues
ULK1 (human): S758‑p, ULK1 (mouse): S757‑p, ULK1 (rat): S757‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), HCT116 (intestinal), SUM149 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  animal studies
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sorafenib, pemetrexed decrease